$9.46
00.00%
At close: Jul 22, 4:00 PM EDT
$9.46
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
Larimar Therapeutics
LRMRNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Larimar Therapeutics (NASDAQ:LRMR) Stock, Analyst Ratings, Price Targets, Forecasts
Larimar Therapeutics Inc has a consensus price target of $19.5 based on the ratings of 5 analysts. The high is $25 issued by JMP Securities on May 31, 2024. The low is $14 issued by Citigroup on May 22, 2024. The 3 most-recent analyst ratings were released by JMP Securities, Citigroup, and JMP Securities on May 31, 2024, May 22, 2024, and May 21, 2024, respectively. With an average price target of $21.33 between JMP Securities, Citigroup, and JMP Securities, there's an implied 125.51% upside for Larimar Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
Citigroup
Leerink Partners
Guggenheim
1calculated from analyst ratings
Analyst Ratings for Larimar Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/31/2024 | Buy Now | 164.27% | JMP Securities | Jonathan Wolleben | $25 → $25 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/22/2024 | Buy Now | 47.99% | Citigroup | Samantha Semenkow | $10 → $14 | Maintains | Buy | Get Alert |
| 05/21/2024 | Buy Now | 164.27% | JMP Securities | Jonathan Wolleben | → $25 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/03/2024 | Buy Now | 164.27% | Leerink Partners | Joori Park | → $25 | Initiates | → Outperform | Get Alert |
| 03/15/2024 | Buy Now | 164.27% | JMP Securities | Jonathan Wolleben | → $25 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/12/2024 | Buy Now | 164.27% | JMP Securities | Jonathan Wolleben | → $25 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/13/2024 | Buy Now | 5.71% | Citigroup | Samantha Semenkow | $4.5 → $10 | Maintains | Buy | Get Alert |
| 02/13/2024 | Buy Now | 164.27% | JMP Securities | Jonathan Wolleben | $17 → $25 | Maintains | Market Outperform | Get Alert |
| 11/17/2023 | Buy Now | -52.43% | Citigroup | Samantha Semenkow | → $4.5 | Upgrade | Neutral → Buy | Get Alert |
| 08/15/2023 | Buy Now | 79.7% | JMP Securities | Jonathan Wolleben | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/18/2023 | Buy Now | -52.43% | Citigroup | Samantha Semenkow | $7 → $4.5 | Maintains | Neutral | Get Alert |
| 05/17/2023 | Buy Now | 47.99% | Guggenheim | Yatin Suneja | $12 → $14 | Maintains | Buy | Get Alert |
| 05/16/2023 | Buy Now | 58.56% | JMP Securities | Jonathan Wolleben | → $15 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/15/2023 | Buy Now | -26% | Citigroup | Samantha Semenkow | → $7 | Maintains | Neutral | Get Alert |
| 03/15/2023 | Buy Now | 26.85% | Guggenheim | Yatin Suneja | → $12 | Reiterates | → Buy | Get Alert |
| 03/14/2023 | Buy Now | 58.56% | JMP Securities | Jonathan Wolleben | $15 → $15 | Maintains | Market Outperform | Get Alert |
| 03/01/2023 | Buy Now | 58.56% | JMP Securities | Jonathan Wolleben | → $15 | Maintains | Market Outperform | Get Alert |
| 01/24/2023 | Buy Now | 69.13% | JMP Securities | Jonathan Wolleben | $16 → $16 | Maintains | Market Outperform | Get Alert |
| 12/13/2022 | Buy Now | -57.72% | Citigroup | Samantha Semenkow | → $4 | Initiates | → Neutral | Get Alert |
| 10/19/2022 | Buy Now | 26.85% | Guggenheim | Yatin Suneja | → $12 | Initiates | → Buy | Get Alert |
| 09/19/2022 | Buy Now | 69.13% | JMP Securities | Jonathan Wolleben | $10 → $16 | Maintains | Market Outperform | Get Alert |
| 09/19/2022 | Buy Now | — | William Blair | Myles Minter | — | Upgrade | Market Perform → Outperform | Get Alert |
| 02/15/2022 | Buy Now | — | William Blair | Myles Minter | — | Downgrade | Outperform → Market Perform | Get Alert |
FAQ
What is the target price for Larimar Therapeutics (LRMR) stock?
The latest price target for Larimar Therapeutics (NASDAQ:LRMR) was reported by JMP Securities on May 31, 2024. The analyst firm set a price target for $25.00 expecting LRMR to rise to within 12 months (a possible 164.27% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Larimar Therapeutics (LRMR)?
The latest analyst rating for Larimar Therapeutics (NASDAQ:LRMR) was provided by JMP Securities, and Larimar Therapeutics reiterated their market outperform rating.
When was the last upgrade for Larimar Therapeutics (LRMR)?
The last upgrade for Larimar Therapeutics Inc happened on November 17, 2023 when Citigroup raised their price target to $4.5. Citigroup previously had a neutral for Larimar Therapeutics Inc.
When was the last downgrade for Larimar Therapeutics (LRMR)?
The last downgrade for Larimar Therapeutics Inc happened on February 15, 2022 when William Blair changed their price target from N/A to N/A for Larimar Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Larimar Therapeutics (LRMR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Larimar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Larimar Therapeutics was filed on May 31, 2024 so you should expect the next rating to be made available sometime around May 31, 2025.
Is the Analyst Rating Larimar Therapeutics (LRMR) correct?
While ratings are subjective and will change, the latest Larimar Therapeutics (LRMR) rating was a reiterated with a price target of $25.00 to $25.00. The current price Larimar Therapeutics (LRMR) is trading at is $9.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.